John Varian - 22 Jun 2023 Form 4 Insider Report for Acorda Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 22 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2023, 17:38:37 UTC
Prior SEC filing: 03 Feb 2023
Next SEC filing: 25 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ John Varian

Key filing fact

John Varian filed Form 4 for Acorda Therapeutics, Inc. on 23 Jun 2023.

Key facts

This page summarizes John Varian's Form 4 filing for Acorda Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jun 2023, 17:38.

Change

Previous filing in this sequence was filed on 03 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACOR transaction Derivative

Non-Employee Stock Option

Award

Transaction value: $0
Shares: +1,200
Change %
Price: $0.000000
Shares after: 1,200
Date: 22 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,200
Exercise price: $12.99
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 22, 2023, with the first quarterly installment vesting on September 22, 2023, subject to continued service on the company's Board of Directors through each vesting date.